San Francisco, CA, United States of America

Maria Consuelo Garcia

USPTO Granted Patents = 3 


Average Co-Inventor Count = 2.6

ph-index = 3

Forward Citations = 43(Granted Patents)


Company Filing History:


Years Active: 2011-2018

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Maria Consuelo Garcia: Innovator in Therapeutic Monoclonal Antibodies

Introduction

Maria Consuelo Garcia is a prominent inventor based in San Francisco, CA. She has made significant contributions to the field of biotechnology, particularly in the development of therapeutic monoclonal antibodies. With a total of 3 patents to her name, her work focuses on neutralizing botulinum neurotoxins, which are critical in the treatment of botulism.

Latest Patents

One of her latest inventions involves therapeutic monoclonal antibodies that specifically bind to and neutralize botulinum neurotoxins, such as BoNT/A, BoNT/B, and BoNT/E. This invention provides antibodies that can effectively neutralize these neurotoxins and are therefore useful in treating botulism. The antibodies and their derivatives can be utilized to target the neutralizing epitopes, enhancing their therapeutic potential.

Career Highlights

Maria is affiliated with the University of California, where she continues her research and development in the field of biotechnology. Her innovative work has positioned her as a key figure in the scientific community, contributing to advancements in medical treatments.

Collaborations

Throughout her career, Maria has collaborated with notable colleagues, including James David Marks and Peter Amersdorfer. These partnerships have further enriched her research and expanded the impact of her inventions.

Conclusion

Maria Consuelo Garcia is a trailblazer in the field of therapeutic monoclonal antibodies, with a focus on combating botulinum neurotoxins. Her contributions are vital for advancing medical treatments and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…